101 related articles for article (PubMed ID: 29848702)
1. Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
Isono M; Sato A; Asano T; Okubo K; Asano T
Anticancer Res; 2018 Jun; 38(6):3493-3500. PubMed ID: 29848702
[TBL] [Abstract][Full Text] [Related]
2. Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells.
Isono M; Sato A; Okubo K; Asano T; Asano T
Oncol Res; 2016; 24(5):327-335. PubMed ID: 27712589
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Sato A; Asano T; Ito K; Asano T
Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
[TBL] [Abstract][Full Text] [Related]
4. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
[TBL] [Abstract][Full Text] [Related]
5. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
Okubo K; REßING N; Schulz WA; Hansen FK; Asano T; Sato A
Anticancer Res; 2021 Dec; 41(12):5987-5996. PubMed ID: 34848452
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress.
Sato A; Asano T; Okubo K; Isono M; Asano T
Oncol Res; 2018 Mar; 26(2):323-332. PubMed ID: 28560953
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2019 Nov; 39(11):5891-5901. PubMed ID: 31704813
[TBL] [Abstract][Full Text] [Related]
9. Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Wang M; Liang L; Lu J; Yu Y; Zhao Y; Shi Z; Li H; Xu X; Yan Y; Niu Y; Liu Z; Shen L; Zhang H
Thorac Cancer; 2019 Apr; 10(4):918-929. PubMed ID: 30883017
[TBL] [Abstract][Full Text] [Related]
10. Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
Sato A; Asano T; Okubo K; Isono M; Asano T
Cancer Sci; 2017 Jun; 108(6):1194-1202. PubMed ID: 28342223
[TBL] [Abstract][Full Text] [Related]
11. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract][Full Text] [Related]
12. Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
Qian G; Yao W; Zhang S; Bajpai R; Hall WD; Shanmugam M; Lonial S; Sun SY
Cancer Lett; 2018 Oct; 435():44-54. PubMed ID: 30059709
[TBL] [Abstract][Full Text] [Related]
13. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Sanchez E; Li M; Li J; Wang C; Chen H; Jones-Bolin S; Hunter K; Ruggeri B; Berenson JR
Leuk Res; 2012 Nov; 36(11):1422-7. PubMed ID: 22906694
[TBL] [Abstract][Full Text] [Related]
14. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
[TBL] [Abstract][Full Text] [Related]
15. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
[TBL] [Abstract][Full Text] [Related]
16. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
de Souza JG; Morais KL; Anglés-Cano E; Boufleur P; de Mello ES; Maria DA; Origassa CS; de Campos Zampolli H; Câmara NO; Berra CM; Bosch RV; Chudzinski-Tavassi AM
Oncotarget; 2016 Sep; 7(38):62255-62266. PubMed ID: 27566592
[TBL] [Abstract][Full Text] [Related]
17. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
Sato A; Asano T; Ito K; Asano T
Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
[TBL] [Abstract][Full Text] [Related]
18. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Sato A; Asano T; Ito K; Sumitomo M; Asano T
BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
[TBL] [Abstract][Full Text] [Related]
20. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
